Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and immunogenicity of RSVpreF coadministered with the herpes zoster vaccine in adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF
• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus (RSV) | Phase 3 | Status: COMPLETED